Provides guidance for the quarter ending June 30, 2025 of $60 – $63 million in net product revenue and cash operating expenses of $45 – $50 million.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Wins Court Ruling for LUMRYZ Expansion
- Avadel Pharmaceuticals announces favorable ruling in appeal of injunction
- Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
- Is AVDL a Buy, Before Earnings?
- Avadel, nference announce publication of data on sodium oxybate